DRI Capital Completes C$600M in Deals in 2012

By Kirk Falconer — 3 years ago

DRI Capital, a Canadian private equity firm specializing in monetizing royalties it purchases from pharmaceutical and biotechnology companies and others, completed over C$600 million in deals in 2012. Among the firm’s disclosed transactions was the September 2012 acquisition of BENLYSTA royalty rights from Weston, Mass.-based Biogen Idec Ltd. DRI Capital, which celebrates its 20th anniversary in 2013, raised its last partnership, Drug Royalty Fund II, totaling C$700 million, in 2010.


DRI Crosses Fundraising Target, Doesn’t Stop

By Erin Griffith — 6 years ago

DRI Capital, a private equity firm which invests in drug royalty streams, has raised $600 million for its second fund, a source familiar with the situation said. The firm originally targeted $500 million for Drug Royalty II LP, but has continued to accept new commitments. DRI Capital’s first fund was a 2006 vintage with $800 […]